| Literature DB >> 25964370 |
Jennifer A Walker1, Christopher J Oliphant2, Alexandros Englezakis2, Yong Yu3, Simon Clare3, Hans-Reimer Rodewald4, Gabrielle Belz5, Pentao Liu3, Padraic G Fallon6, Andrew N J McKenzie1.
Abstract
Group 2 innate lymphoid cells (ILC2s) are often found associated with mucosal surfaces where they contribute to protective immunity, inappropriate allergic responses, and tissue repair. Although we know they develop from a common lymphoid progenitor in the bone marrow (BM), the specific lineage path and transcriptional regulators that are involved are only starting to emerge. After ILC2 gene expression analysis we investigated the role of Bcl11b, a factor previously linked to T cell commitment, in ILC2 development. Using combined Bcl11b-tom and Id2-gfp reporter mice, we show that Bcl11b is expressed in ILC2 precursors in the BM and maintained in mature ILC2s. In vivo deletion of Bcl11b, by conditional tamoxifen-induced depletion or by Bcl11b(-/-) fetal liver chimera reconstitution, demonstrates that ILC2s are wholly dependent on Bcl11b for their development. Notably, in the absence of Bcl11b there is a concomitant expansion of the RORγt(+) ILC3 population, suggesting that Bcl11b may negatively regulate this lineage. Using Nippostrongylus brasiliensis infection, we reveal that the absence of Bcl11b leads to impaired worm expulsion, caused by a deficit in ILC2s, whereas Citrobacter rodentium infection is cleared efficiently. These data clearly establish Bcl11b as a new factor in the differentiation of ILC2s.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25964370 PMCID: PMC4451131 DOI: 10.1084/jem.20142224
Source DB: PubMed Journal: J Exp Med ISSN: 0022-1007 Impact factor: 14.307
Figure 1.Bcl11b is expressed throughout the ILC2 lineage. (a–f) Bcl11b-tom in cells isolated from Bcl11btom/+ mice, assessed by flow cytometry. (a and b) Bcl11b-tom expression in ILC2s and CD4+ T cells from the MLN (a) and ILC2s from FALC (lin−CD45+KLRG1+) and siLP (lin−CD45+ICOS+KLRG1+; b) of Bcl11b+/+ and Bcl11btom/+ mice. (c and d) Bcl11b-tom expression in ILC2s from lung (c) and MLN (d) of mice with the indicated genotypes after administration of IL-25 or IL-33. (e) Expression of Bcl11b-tom in BM ILC2ps (gated as shown). (f) Bcl11b-tom expression in ILC3 subsets (as indicated) from siLP of Bcl11btom/+ mice (black). Bcl11b-tom expression in ILC2s from siLP is shown for comparison (red). (a–f) Numbers adjacent to boxed areas indicate the relative percentage of gated populations. Gating strategies and phenotypic analysis are presented in Figs. S1 and S2. Data represent at least two independent experiments with three mice per group.
Figure 2.Bcl11b expression defines ILC2ps in the BM. (a–n) ICOS+CD244− (ILC2p), ICOS+CD244+, ICOS−CD244+ (NKp), and ICOS−CD244− subsets were isolated from lin−Id2-gfp+ BM cells and cultured in vitro (a–c, e, l, and m) or adoptively transferred into alymphoid recipients (f, g, i, and j) to assess their lineage potential; flow cytometry of lin−Id2-gfp+ subsets (d, h, k, and n) is shown. (a and b) The phenotype of the indicated cell populations cultured for 11 d on OP9-DL1 stromal cells in the presence of IL-7 and IL-33 (a) or cultured for 11 d on OP9 stromal cells in the presence of IL-7 and IL-15 (b). (c) Cells (1,000 per well) were cultured for 11 d under the conditions indicated. Bar graph depicts the number of cells in the final culture represented by ILC2s (Id2-gfp+ICOS+) and NK cells (NKp46+NK1.1+). Shown are mean ± SEM pooled from two independent experiments with two to three technical replicates per group. (d) Bcl11b-tom expression in ILC2p (lin−Id2-gfp+ICOS+CD244−) and NKp (lin−Id2-gfp+ICOS−CD244+) cells. (e) Bcl11b-tom expression in ILC2ps after culture on OP9-DL1 stromal cells for 13 d in the presence of IL-7 and IL-33. (f and g) ILC2ps (f) and NKps (see Fig. S2 c for gating; g) were adoptively transferred into Rag2 recipients (∼700 cells per recipient). Plots show flow cytometric analysis of progeny, identified by Id2-gfp+ expression (Fig. S2 d), from spleen at 3 wk after transfer. (h) Surface marker expression of NKp, ILC2p, and LSI progenitor cell populations, gated as indicated in Fig. S2 e. (i and j) Approximately 700 ILC2p (lin−Flt3−Id2-gfp+ICOS+Bcl11b+) or LSI (lin−Sca-1+Id2-gfp+) cells (see Fig. S2 f for gating) were adoptively transferred into Rag2 recipients. Plots show flow cytometric analysis of progeny, identified by Id2-gfp+ expression, from siLP at 6 wk after transfer (i), and panel j shows intracellular Gata3 staining of progeny. (k) Bcl11b-tom expression in ICOS−CD244− and ICOS+CD244+ subsets. (l and m) The phenotype of Bcl11b− and Bcl11b+ fractions of the ICOS−CD244− population, after culture for 11 d on OP9-DL1 stromal cells in the presence of IL-7 and IL-33 (l) or on OP9 stromal cells in the presence of IL-7 and IL-15 (m). (n) Intracellular Gata3 staining was assessed on lin− BM cells, sorted as indicated. (d, h, and k) Data represent at least three independent experiments with at least three mice per group. (a–c, e, l, and m) Data represent two independent experiments with two to three technical replicates per group. (f, g, and i) Data represent two independent experiments with three mice per group. (j) Data represent a single experiment using cells pooled from three mice. (n) Data represent two independent experiments using cells pooled from three mice.
Figure 3.ILC2s fail to develop in the absence of Bcl11b. (a–k) Flow cytometry was performed to enumerate the indicated cell populations in conditional Bcl11b-deficient mice (a–f) or chimeras generated using Bcl11b FL cells (g–k). (a and b) MLN ILC2s (a) and BM ILC2ps (b) in Cre-ERT2; Bcl11b mice, treated as indicated (Veh, vehicle control; Tx, tamoxifen). Shown is mean ± SEM from two similar experiments with three to four mice per group. (c) Intracellular Gata3 staining in ILC2s from the MLNs of Cre-ERT2; Bcl11b mice, treated as indicated. (d–f) MLN ILC2 (d), splenic CD3+ (e), and splenic NK1.1+ cells (f) after the administration of tamoxifen and IL-33 (+/− = Cre-ERT2; Bcl11b; flox/− = Cre-ERT2; Bcl11b). Mean ± SEM from two similar experiments with two to three mice per group. (g) The indicated cell populations were enumerated in mice 6–8 wk after reconstitution with either Bcl11b or Bcl11b CD45.2+ FL, mixed with CD45.1+ BM. Bars represent mean ± SEM of five mice per group. Data represent three independent experiments. (h) ILC2s (lin−Id2-gfp+ICOS+KLRG1+) in the MLN of mice reconstituted as in panel g, after PBS or IL-33 administration. (i–k) BM ILC2ps (lin−Id2-gfp+Sca-1+ST2+; i), siLP ILC2s (lin−Id2-gfp+KLRG1+) and NCR+ ILC3s (lin−Id2-gfp+NKp46+; j) and MLN ILC2s and NCR+ ILC3s (k) in mice reconstituted as in panel g; (h–j) mean ± SEM; (k) mean ± SD. P-values refer to Student’s t test analysis: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 4.Bcl11b is essential for clearance of (a–h) Bcl11b-deficient FL cells were used to generate chimeric mice that were either partially (ILC2s only; a and b) or fully deficient in Bcl11b (c–h). These chimeras were challenged with N. brasiliensis (a and b) or C. rodentium (c–h), and the indicated cell populations were enumerated by flow cytometry. (a and b) MLN ILC2 numbers (a) and intestinal worm burdens (b). Data represent two independent experiments with five to six mice per group; (a) mean ± SD; (b) mean ± SEM. (c and d) Weights after C. rodentium infection (single experiment with three mice per group; mean ± SD). (e) Bacterial load after C. rodentium infection (mean ± SEM). (f–h) Identification (f) and number (g) of ILC2 (lin−CD45+Id2-gfp+IL7Rα+KLRG1+), ILC3 (lin−CD45+Id2-gfp+IL7Rα+NKp46+ KLRG1−; mean ± SD), and KLRG1lo cells (lin−CD45+Id2-gfp+IL7Rα+ NKp46+KLRG1lo) and intracellular staining of lineage− cells in the siLP (h) at day 26 p.i. with C. rodentium. (c and e–h) Data represent two independent experiments with eight to nine mice per group. P-values refer to Student’s t test analysis: *, P < 0.05; **, P < 0.01; ***, P < 0.001.